PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrom… Read more
PaxMedica, Inc. Common Stock (PXMD) - Net Assets
Latest net assets as of September 2024: $-1.93 Million USD
Based on the latest financial reports, PaxMedica, Inc. Common Stock (PXMD) has net assets worth $-1.93 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($820.38K) and total liabilities ($2.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.93 Million |
| % of Total Assets | -235.45% |
| Annual Growth Rate | 315.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3361.98 |
PaxMedica, Inc. Common Stock - Net Assets Trend (2018–2023)
This chart illustrates how PaxMedica, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PaxMedica, Inc. Common Stock (2018–2023)
The table below shows the annual net assets of PaxMedica, Inc. Common Stock from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $3.39 Million | +3011.28% |
| 2022-12-31 | $108.80K | +101.08% |
| 2021-12-31 | $-10.11 Million | -118.40% |
| 2020-12-31 | $-4.63 Million | -4608.54% |
| 2019-12-31 | $-98.30K | -3712.68% |
| 2018-12-31 | $2.72K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PaxMedica, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5180036600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $740.00 | 0.02% |
| Other Comprehensive Income | $-740.00 | -0.02% |
| Other Components | $55.41 Million | 1637.03% |
| Total Equity | $3.39 Million | 100.00% |
PaxMedica, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of PaxMedica, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CANFOR PULP (8CP.SG)
STU:8CP
|
$2.17K |
|
ELEMENTOS (9EM.SG)
STU:9EM
|
$2.18K |
|
PRIMAG (P9R.SG)
STU:P9R
|
$2.18K |
|
TetraLogic Pharmaceuticals Corp
PINK:TLOG
|
$2.18K |
|
Kohinoor Industries Ltd
KAR:KOIL
|
$2.16K |
|
Converge Information & Communications Technology Solutions Inc
PSE:CNVRG
|
$2.16K |
|
PEAK RES
BE:M3U
|
$2.16K |
|
GOAT Industries Ltd.
F:26B
|
$2.16K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PaxMedica, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 108,800 to 3,385,073, a change of 3,276,273 (3011.3%).
- Net loss of 18,290,000 reduced equity.
- Dividend payments of 11,945,936,005 reduced retained earnings.
- Share repurchases of 195,997 reduced equity.
- New share issuances of 5,006,479 increased equity.
- Other comprehensive income decreased equity by 740.
- Other factors increased equity by 11,962,692,536.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.29 Million | -540.31% |
| Dividends Paid | $11.95 Billion | -352900.4% |
| Share Repurchases | $196.00K | -5.79% |
| Share Issuances | $5.01 Million | +147.9% |
| Other Comprehensive Income | $-740.00 | -0.02% |
| Other Changes | $11.96 Billion | +353395.41% |
| Total Change | $- | 3011.28% |
Book Value vs Market Value Analysis
This analysis compares PaxMedica, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.72x to 0.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $-0.17 | $0.00 | x |
| 2020-12-31 | $-7.86 | $0.00 | x |
| 2021-12-31 | $-14.59 | $0.00 | x |
| 2022-12-31 | $0.21 | $0.00 | x |
| 2023-12-31 | $2.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PaxMedica, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -540.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.68x
- Recent ROE (-540.31%) is above the historical average (-2829.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-588.78K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.03 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.02 Million |
| 2022 | -13604.78% | 0.00% | 0.00x | 20.26x | $-14.81 Million |
| 2023 | -540.31% | 0.00% | 0.00x | 1.68x | $-18.63 Million |
Industry Comparison
This section compares PaxMedica, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PaxMedica, Inc. Common Stock (PXMD) | $-1.93 Million | 0.00% | N/A | $2.17K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |